S
Sensus Healthcare, Inc.
SRTSCIK 0001494891NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$27.48M
Net Income
$-7.72M
Total Assets
$53.04M
Equity
$48.10M
Shares Out
16.46M
Op. Cash Flow
$528.0K
Business
Sensus Healthcare, Inc. develops and markets proprietary low-energy superficial radiation therapy (SRT) systems for treating oncological and non-oncological skin conditions. Its product portfolio includes the SRT-100, SRT-100 Vision, and SRT-100+, plus service contracts (Sentinel), consumables, lasers, and a transdermal infusion product in development. The company operates as a single business segment providing devices, installation, commissioning, clinical training, and operational healthcare services. It distributes primarily in the United States via direct sales and internationally through dealers, targeting dermatology, radiation oncology, plastic surgery and aesthetic markets.
Summary from filing dated 2025-03-05
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 27 | 42 | 24 | — | — | |
| Cost of sales | 16 | 17 | 10 | 15 | 10 | |
| Gross profit | 12 | 24 | 14 | 30 | 17 | |
| General and administrative | 8 | 7 | 5 | — | — | |
| Selling and marketing | 7 | 5 | 6 | 6 | 5 | |
| Research and development | 8 | 4 | 4 | 3 | 3 | |
| Total operating expenses | 22 | 16 | 14 | 15 | 13 | |
| (Loss) income from operations | −10 | 8 | −382,000 | 15 | 4 | |
| Interest income, net | 683,000 | 932,000 | — | — | — | |
| Other income, net | 683,000 | 932,000 | 1 | 13 | — | |
| (Loss) income before income taxes | −10 | 9 | 652,000 | 28 | 4 | |
| (Benefit from) provision for income taxes | −2 | 2 | 167,000 | 4 | — | |
| Net (loss) income | −8 | 7 | 485,000 | 24 | 4 | |
| Net (loss) income per share - basic | −0.47 | 0.41 | 0.03 | 1.47 | 0.25 | |
| Net (loss) income per share - diluted | −0.47 | 0.41 | 0.03 | 1.46 | 0.25 | |
| Weighted average number of shares used in computing net (loss) income per share - basic | 16 | 16 | 16 | 16 | 16 | |
| Weighted average number of shares used in computing net (loss) income per share - diluted | 16 | 16 | 16 | 17 | 17 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 22 | 23 | 26 | 15 | |
| Accounts receivable, net | 6 | 20 | 11 | 17 | 12 | |
| Inventories | 15 | 10 | 12 | 4 | 2 | |
| Prepaid inventory | 2 | 3 | 3 | 6 | — | |
| Other current assets | 2 | 2 | 888,000 | 660,000 | — | |
| Total current assets | 46 | 57 | 50 | 53 | 31 | |
| Property and equipment, net | 2 | 2 | 464,000 | 243,000 | 605,000 | |
| Deferred tax assets, net | 4 | 2 | 2 | 2 | — | |
| Operating lease right-of-use assets, net | 452,000 | 581,000 | 774,000 | 996,000 | 169,000 | |
| Other noncurrent assets | 640,000 | 652,000 | 804,000 | 542,000 | — | |
| Total assets | 53 | 62 | 54 | 57 | 32 | |
| Accounts payable and accrued expenses | 3 | 5 | 3 | 6 | 4 | |
| Product warranties | 275,000 | 329,000 | 538,000 | 403,000 | 508,000 | |
| Operating lease liabilities, current portion | 262,000 | 204,000 | 187,000 | 190,000 | 174,000 | |
| Deferred revenue, current portion | 842,000 | 541,000 | 657,000 | 693,000 | 1 | |
| Total current liabilities | 5 | 6 | 4 | 8 | 6 | |
| Operating lease liabilities | 209,000 | 398,000 | 596,000 | 830,000 | — | |
| Deferred revenue, net of current portion | 10,000 | 55,000 | 60,000 | 139,000 | 262,000 | |
| Total liabilities | 5 | 6 | 5 | 9 | 6 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | — | — | — | — | — | |
| Common stock, $0.01 par value 50,000,000 authorized; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025; 17,036,845 issued and 16,495,396 outstanding at December 31, 2024 | 169,000 | 169,000 | 169,000 | 169,000 | 167,000 | |
| Additional paid-in capital | 46 | 46 | 45 | 45 | — | |
| Treasury stock, 593,036 and 541,449 shares at cost, at December 31, 2025 and December 31, 2024, respectively | −4 | −4 | −4 | −3 | −325,000 | |
| Retained earnings | 6 | 13 | 7 | 6 | −18 | |
| Total stockholders equity | 48 | 56 | 49 | 48 | 26 | |
| Total liabilities and stockholders equity | 53 | 62 | 54 | 57 | 32 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Credit loss expense | 44,000 | 123,000 | 7,000 | 145,000 | 78,000 | |
| Depreciation | 386,000 | 239,000 | — | — | — | |
| Amortization of right-of-use asset | 240,000 | 193,000 | 186,000 | 194,000 | — | |
| Provision for product warranties | 503,000 | 255,000 | 603,000 | 722,000 | 530,000 | |
| Stock-based compensation | 295,000 | 323,000 | 328,000 | 187,000 | 415,000 | |
| Deferred income taxes | −2 | −57,000 | −427,000 | −2 | — | |
| Accounts receivable | 14 | −9 | 7 | −5 | — | |
| Inventories | −5 | 268,000 | −9 | −3 | 3 | |
| Prepaid inventory | 2 | −361,000 | 3 | −5 | — | |
| Other current assets | −176,000 | −619,000 | −228,000 | 711,000 | — | |
| Other noncurrent assets | 12,000 | 152,000 | −312,000 | −417,000 | — | |
| Accounts payable and accrued expenses | −1 | 2 | −3 | 799,000 | 962,000 | |
| Operating lease liability | −242,000 | −181,000 | −201,000 | −199,000 | — | |
| Income tax payable | — | −37,000 | −853,000 | 890,000 | — | |
| Deferred revenue | 256,000 | −121,000 | −115,000 | −602,000 | −637,000 | |
| Product warranties | −557,000 | −464,000 | −468,000 | −827,000 | — | |
| Net cash provided by (used in) operating activities | 528,000 | −831,000 | −2 | −1 | −286,000 | |
| Acquisition of property and equipment | −196,000 | −276,000 | −229,000 | −159,000 | −128,000 | |
| Net cash used in investing activities | −196,000 | −276,000 | −187,000 | 15 | 129,000 | |
| Repurchase of common stock | −300,000 | — | −27,000 | −3 | — | |
| Withholding taxes on stock-based compensation | −5,000 | −52,000 | −59,000 | −109,000 | — | |
| Exercise of stock options | — | 67,000 | 46,000 | 731,000 | — | |
| Net cash (used in) provided by financing activities | −305,000 | 15,000 | −40,000 | −2 | −231,000 | |
| Net increase (decrease) in cash and cash equivalents | 27,000 | −1 | −2 | 11 | −388,000 | |
| Interest paid | — | — | — | 2,000 | 2,000 | |
| Income tax paid | 980,000 | 3 | 1 | 5 | — | |
| Income tax refunds received | 395,000 | — | — | — | — | |
| Net transfers from inventory to fixed assets | 169,000 | 1 | — | — | — | |
| Lease liability arising from obtaining right-of-use-assets | 111,000 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro